ArticleRegenerative therapy2019
The secretome of adipose-derived mesenchymal stem cells attenuates epithelial-mesenchymal transition in human corneal epithelium.
Article in Regenerative therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Adipose-Derived Stem Cells in Ophthalmic Regenerative Medicine: From Cell Replacement to Precision Engineering.Stem cell reviews and reports · 2026Review
- Effects of secretome derived from resveratrol treated mesenchymal stem cell on cornea wound: an organ culture study.Scientific reports · 2026Article
- Review
- Evaluating the efficacy of stem cells in treating severe dry eye disease.World journal of stem cells · 2025Review
- Spatially controlled multicellular differentiation of stem cells using triple factor-releasing metal-organic framework-coated nanoline arrays.Nature communications · 2025Article
- Unlocking the versatile potential: Adipose-derived mesenchymal stem cells in ocular surface reconstruction and oculoplastics.World journal of stem cells · 2024Review
- Focus on seed cells: stem cells in 3D bioprinting of corneal grafts.Frontiers in bioengineering and biotechnology · 2024Review
- Ocular instillation of conditioned medium from mesenchymal stem cells is effective for dry eye syndrome by improving corneal barrier function.Scientific reports · 2023Article
- Human Wharton's Jelly Mesenchymal Stem Cell Secretome Modifies the Processes of Neuroprotection and Epithelial-Mesenchymal Transition in Retinal Pigment Epithelium at Transcriptional Level.Molecular biology reports · 2023Article
- Adipose Stem Cells in Modern-Day Ophthalmology.Clinics and practice · 2023Review
- Current and Emerging Therapies for Limbal Stem Cell Deficiency.Stem cells translational medicine · 2022Article
- Article
- Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease.International journal of molecular sciences · 2021Review
- Therapeutic effect of secretome from TNF-α stimulated mesenchymal stem cells in an experimental model of corneal limbal stem cell deficiency.International journal of ophthalmology · 2021Article
- Novel Cell Culture Paradigm Prolongs Mouse Corneal Epithelial Cell Proliferative ActivityFrontiers in cell and developmental biology · 2021Article
- Therapeutic Effects of Lyophilized Conditioned-Medium Derived from Corneal Mesenchymal Stromal Cells on Corneal Epithelial Wound Healing.Current eye research · 2020Article
- Cellular therapy of corneal epithelial defect by adipose mesenchymal stem cell-derived epithelial progenitors.Stem cell research & therapy · 2020Article
- Mesenchymal Stromal Cell-Based Therapy for Dry Eye: Current Status and Future Perspectives.Cell transplantationReview
- Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery.Expert opinion on biological therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEpithelial-mesenchymal transition (EMT) induces the loss of cell-cell interactions in polarized epithelial cells and converts these cells to invasive mesenchymal-like cells. It is also involved in tissue fibrosis including that occurring in some ocular surface diseases such as pterygium and in subepithelial corneal fibrosis in limbal stem cell deficiency. Here, we examined the effects of the secretome of human adipose-derived mesenchymal stem cells (AdMSCs) on EMT in human corneal epithelial cells (CECs).
methodsEMT was induced with transforming growth factor-β (TGF-β) in primary human CECs isolated from the human corneal limbus. The effects of the AdMSC secretome on EMT in these cells or stratified CEC sheets were analyzed by co-cultivation experiments with the addition of AdMSC conditioned-medium. The expression of EMT-related genes and proteins in CECs was analyzed. The superstructure of CECs was observed by scanning electron microscopy. Furthermore, the barrier function of CEC sheets was analyzed by measuring transepithelial electrical resistance (TER).
resultsThe AdMSC secretome was found to suppress EMT-related gene expression and attenuate TGF-β-induced corneal epithelial dysfunction including the dissociation of cell-cell interactions and decreases in TER in constructed CEC sheets.
conclusionsThe secretome of AdMSCs can inhibit TGF-β-induced EMT in CECs. These findings suggest that this could be a useful source for the treatment for EMT-related ocular surface diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.